Larimar Q2 net loss $21.6M; cash $226.1M; OLE interim data Q4; FDA START program

Larimar Therapeutics, Inc.

2024-Q2 EPS reported -$0.62

Net loss $21.6M ($0.34/sh) vs $8.4M loss in Q2 2023; R&D spend $19.7M up from $5.9M on manufacturing.
Cash, equivalents and marketable securities $226.1M at June 30; projected runway into 2026.
Open-label extension study all 7 sites activated; interim data planned Q4 2024.
FDA selected nomlabofusp for START pilot to accelerate development; BLA submission targeted 2H 2025.
Planning PK run-in study in adolescents by year-end 2024; global confirmatory study by mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.